Catheterization and Cardiovascular Interventions

Journal

Publication Venue For

  • Genotype-guided antiplatelet therapy for acute coronary syndrome percutaneous coronary intervention patients: A new standard of care?.  97:795-796. 2021
  • Antiplatelet therapy regimen and duration after percutaneous coronary intervention: Combining prediction scores with clinical judgment.  97:579-580. 2021
  • A new intravascular ultrasound-guided stenting strategy compared with angiography on stent expansion and procedural outcomes in patients with positive lesion remodeling.  97:237-244. 2021
  • Everolimus eluting bioresorbable vascular scaffolds for infrapopliteal critical limb ischemia: Moving beyond grasping at metal straws.  97:150-151. 2021
  • Ticagrelor monotherapy: When is mono-antiplatelet therapy (MAPT) equivalent or better?.  96:1379-1380. 2020
  • Codeployment of a percutaneous edge-to-edge mitral valve repair device and a ventriculoseptal defect occluder device to address complex mitral regurgitation with leaflet perforation.  96:1333-1338. 2020
  • Radial access and risk guided use of bivalirudin?.  96:1249-1250. 2020
  • Safety and efficacy of paclitaxel drug-coated balloon treatment of femoropopliteal claudicants: Data and analytic methods matter.  96:1100-1101. 2020
  • A step toward physiologically guided chronic limb-threatening ischemia intervention.  96:913-914. 2020
  • Insulin-treated diabetes mellitus: An actionable risk factor and marker after percutaneous coronary intervention.  96:309-310. 2020
  • A step forward in predicting anterograde crossing success for infrapopliteal chronic total occlusions.  95:756-757. 2020
  • Prior probability of significant obstructive arterial disease in the contralateral lower extremity.  95:307-308. 2020
  • Clopidogrel pretreatment may reduce early acquired thrombocytopenia after transcatheter aortic valve replacement (TAVR).  94:818-819. 2019
  • Costs of postoperative delirium with transcatheter aortic valve replacement: Improved yet still present.  93:1137. 2019
  • Intravascular ultrasound of normal left main arteries: Insights for stent optimization and standardization.  93:239-240. 2019
  • Embolic stroke of undetermined source and patent foramen ovale closure: Practice insights from meta-analysis?.  92:1161-1162. 2018
  • Anchor balloon, buddy wire, and wire and sheath techniques to deploy percutaneous pulmonary valves in tetralogy of fallot patients.  92:915-920. 2018
  • “Expanding the frame” for valve-in-valve therapy in small bioprostheses: Encouraging signs for the road ahead.  92:555-556. 2018
  • Surgical aortic valve replacement and transcatheter aortic valve implantation for severe aortic stenosis: Equipoise remains a tenable assumption.  92:431-432. 2018
  • Patent foramen ovale closure for cryptogenic stroke: Effective, but only in select patients.  92:174-175. 2018
  • Long-term survival prospects of patients undergoing percutaneous coronary intervention: Envisioning the future.  91:696. 2018
  • The promise of effective P2Y12 platelet receptor pretreatment: Not crushed yet.  91:251-252. 2018
  • Patient preference: An important emerging factor in operator access site selection.  91:25-26. 2018
  • Individualizing dual antiplatelet therapy duration: Prediction tools, genomics, and clinical judgment.  90:38. 2017
  • Length and pressure matter: Expediting evidence-based progress in femoropoliteal intervention.  89:1257-1258. 2017
  • The many radial access learning curves.  89:865-866. 2017
  • Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.  89:E99-E103. 2017
  • Unprotected Left Main Disease and Percutaneous Intervention: A Prototype for Precision Medicine.  89:11-12. 2017
  • Radial Access Optimization in the Nascent Post-Adoption Era.  88:1044-1045. 2016
  • Bioresorbable vascular scaffolds in coronary bifurcation lesions: The next frontiers?.  88:870-871. 2016
  • Routine invasive evaluation in non ST elevation myocardial infarction (NSTEMI-ACS): Optimizing best.  88:775-776. 2016
  • End of the bare metal stent era?.  88:49-50. 2016
  • Emergent transcatheter mitral valve-in-valve implantation in a patient with cardiogenic shock secondary to a failed mitral bioprosthesis.  87:1342-1346. 2016
  • Simultaneous transcatheter pulmonary and tricuspid valve-in-valve implantation for the treatment of failing pulmonary and tricuspid bioprostheses.  87:1352-1355. 2016
  • SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of India, and sociedad Latino Americana de Cardiologbox drawings light down and lefta intervencionista).  87:E202-E223. 2016
  • SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologbox drawings light down and lefta Intervencionista).  87:895-899. 2016
  • Risk-guided use of the direct thrombin inhibitor bivalirudin.  87:401-402. 2016
  • Diagnostic cutoff for pressure drop coefficient in relation to fractional flow reserve and coronary flow reserve: A Patient-Level Analysis.  87:273-282. 2016
  • Insulin-treated diabetes mellitus: An important, actionable risk marker after coronary stenting.  87:63-64. 2016
  • Obesity and percutaneous coronary intervention outcomes: Beware the extremes.  85:959-960. 2015
  • Percutaneous coronary intervention: Ever closer to real world silver bullets!?.  85:807-808. 2015
  • Can femoral access bleeding outcomes be improved?.  85:380-381. 2015
  • Diabetes is not sufficient justification for IIb/IIIa use in percutaneous coronary intervention.  86:376-377. 2015
  • Optimal DAPT duration: Each in their own time.  85:41-42. 2015
  • Renal artery stenting: Patient selection post-CORAL.  86:310-311. 2015
  • Shorter (≤ 6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: A meta-analysis of randomized clinical trials.  85:34-40. 2015
  • Cardioprotective effect of high-dose intragraft adenosine infusion on microvascular function and prevention of no-reflow during saphenous vein grafts intervention.  83:1045-1054. 2014
  • Functional diagnosis of coronary stenoses using pressure drop coefficient: A pilot study in humans.  83:377-385. 2014
  • 12-month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: Beyond balloon angioplasty.  84:555-564. 2014
  • Drug-eluting stents for ostial coronary stenoses: Perspectives on the horizon.  82:735-736. 2013
  • Outcomes of carotid stenting in patients with previous neck radiation.  82:689-695. 2013
  • Thromboaspiration and IIb/IIIa therapy in STEMI: Abciximab redux?.  82:612-613. 2013
  • Stent paleology: Diabetic lessons from extinct stents.  81:1125-1126. 2013
  • Diabetes and everolimus-eluting stents: Good offense scores but defense wins tough games.  81:766-767. 2013
  • Embozene™ microspheres induced nonreperfused myocardial infarction in an experimental swine model.  81:689-697. 2013
  • Saphenous vein grafts: Two substrates, two treatments?.  80:1137. 2012
  • Benefit of renal artery stenting: Is on-target therapy the observational bias?.  80:351. 2012
  • Rotational atherectomy for heavily calcified unprotected left main disease: Proceed with caution.  80:221. 2012
  • Implicit rationing of percutaneous coronary intervention: The left main test case.  79:1117. 2012
  • Left main coronary stenosis and acute myocardial infarction: Stent or surgery? An evolving perspective.  79:988-989. 2012
  • Diabetes and percutaneous coronary intervention drug-eluting: Stents whenever feasible.  78:718-719. 2011
  • Quality assessment and improvement in interventional cardiology: A position statement of the society of cardiovascular angiography and interventions, Part II: Public reporting and risk adjustment.  78:493-502. 2011
  • Shock and age: The role of an early invasive strategy.  78:512-513. 2011
  • A novel clinical prediction rule for 30-day mortality following balloon aortic valuloplasty: The CRRAC the AV score.  78:112-118. 2011
  • Quality assessment and improvement in interventional cardiology: A position statement of the Society of Cardiovascular Angiography and Interventions, part 1: Standards for quality assessment and improvement in interventional cardiology.  77:927-935. 2011
  • A full toolbox fixes the roadblocks.  77:759-760. 2011
  • DES in SVGs: Safe and at least short-term effective.  77:356-357. 2011
  • The outcome of pulmonary artery stents following surgical manipulation.  77:390-394. 2011
  • Takotsubo cardiomyopathy and microvascular dysfunction: Another diagnostic criteria or predisposing factor?.  77:132-133. 2011
  • High glycemic stenting menu.  76:934-935. 2010
  • Physiological assessment of renal artery stenosis: Comparisons of resting with hyperemic renal pressure measurements.  76:726-732. 2010
  • Drug-eluting or bare metal stents for diabetics: Clinical judgment still wins.  76:482-483. 2010
  • The holy grail for DES: Does efficacy translate into real world effectiveness?.  76:381-382. 2010
  • Prediction of hemodialysis graft patency by intragraft pressure measurements: Prognostic or reflective?.  76:212-213. 2010
  • Which DES for diabetics? Round 1: A draw. Round 2: Everolimus leading?.  76:58-59. 2010
  • Pulmonary artery stents: Long-term follow-up.  75:757-764. 2010
  • Bifurcation stenting: A commitment to always kiss.  75:614-615. 2010
  • Intravascular ultrasound optimization of drug-eluting stents: Still not enough data.  75:584-585. 2010
  • Hemodynamic and intravascular ultrasound assessment of myocardial bridging: Fractional flow reserve paradox with dobutamine versus adenosine.  75:229-236. 2010
  • As goes the access, so goes the intervention?.  74:932-933. 2009
  • Defining a new standard for IVUS optimized drug-eluting stent implantation - The PRAVIO study: Do we know the right technique for stent optimization?.  74:357-358. 2009
  • The modern axis of peri-procedural evil.  74:56-57. 2009
  • Multivessel disease in diabetics: Does DES level the field?.  73:881-882. 2009
  • A third dimension to uncloud the funnel plot of operator quality.  73:595-596. 2009
  • Long-term follow-up of the STARFlex® device for closure of secundum atrial septal defect.  73:190-195. 2009
  • Length matters: outcomes of superficial femoral artery (SFA) endovascular interventions..  74:1096. 2009
  • Stent fractures in congenital heart disease.  72:977-982. 2008
  • Native vessel PCI in the diabetic: DES whenever feasible.  72:608-609. 2008
  • Hemodynamic evaluation of coronary artery bypass graft lesions using fractional flow reserve.  72:479-485. 2008
  • Myocardial protection with a beta blocker and glycoprotein IIb/IIIa inhibitor during PCI: Attractive concept, but limited evidence of benefit.  72:498-499. 2008
  • Time is muscle; but should it be D2B or D2T?.  72:424-425. 2008
  • Fractional flow reserve: FFR B4 U stent.  72:257-258. 2008
  • The bone marrow and endovascular therapy.  72:210-211. 2008
  • DES in saphenous bypass grafts: A treatment in vain?.  72:21-22. 2008
  • Feasibility of primary clot extraction prior to percutaneous coronary intervention in acute myocardial infarction.  71:870-876. 2008
  • Platelet glycoprotein IIb/IIIa receptor inhibitors: Is their future as bright as their past?.  71:907-908. 2008
  • A revisit: Repeat stent placement versus angioplasty alone for renal in-stent restenosis.  71:706-707. 2008
  • Hemodynamic and intravascular ultrasound assessment of an ambiguous left main coronary artery stenosis.  70:721-730. 2007
  • Renal hemodynamics: Theory and practical tips.  69:894-901. 2007
  • Origin of all three major coronary arteries from the right sinus of valsalva: Clinical, angiographic, and magnetic resonance imaging findings and incidence in a select referral population.  69:711-718. 2007
  • B-type natriuretic peptide level in a patient with constrictive pericarditis.  68:832-834. 2006
  • Fatal subclavian stent infection remote from implantation.  65:535-539. 2005
  • Cypher drug-eluting stent treatment of tibioperoneal obstructive disease: A case report.  64:237-241. 2005
  • Carotid stenting for symptomatic radiation-induced arteritis complicated by recurrent aneurysm formation.  63:507-511. 2004
  • Physiological and intravascular ultrasound assessment of an ambiguous left main coronary artery stenosis.  62:349-357. 2004
  • Long-Term Follow-Up of Brachytherapy for Treatment of Allograft In-Stent Restenosis.  61:217-221. 2004
  • High-output congestive heart failure successfully treated with transcatheter coil embolization of a large renal arteriovenous fistula.  63:373-376. 2004
  • Conflicting functional assessment of stenoses in patients with previous myocardial infarction.  59:489-495. 2003
  • Thermography basket catheter: In vivo measurement of the temperature of atherosclerotic plaques for detection of vulnerable plaques.  59:52-59. 2003
  • How to define coronary stenosis severity?.  53:202-203. 2001
  • Acute alveolar hemorrhage and orthodeoxia induced by intravenous amiodarone..  47:61-63. 1999
  • International Standard Serial Number (issn)

  • 1522-1946
  • Electronic International Standard Serial Number (eissn)

  • 1522-726X